These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 23651191)

  • 61. Virus-induced tumor inflammation facilitates effective DC cancer immunotherapy in a Treg-dependent manner in mice.
    Woller N; Knocke S; Mundt B; Gürlevik E; Strüver N; Kloos A; Boozari B; Schache P; Manns MP; Malek NP; Sparwasser T; Zender L; Wirth TC; Kubicka S; Kühnel F
    J Clin Invest; 2011 Jul; 121(7):2570-82. PubMed ID: 21646722
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Inhibition of topoisomerase I shapes antitumor immunity through the induction of monocyte-derived dendritic cells.
    Lee JM; Shin KS; Koh CH; Song B; Jeon I; Park MH; Kim BS; Chung Y; Kang CY
    Cancer Lett; 2021 Nov; 520():38-47. PubMed ID: 34224797
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Personalized dendritic cell-based tumor immunotherapy.
    Janikashvili N; Larmonier N; Katsanis E
    Immunotherapy; 2010 Jan; 2(1):57-68. PubMed ID: 20161666
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Dendritic cell-based vaccines: barriers and opportunities.
    Cintolo JA; Datta J; Mathew SJ; Czerniecki BJ
    Future Oncol; 2012 Oct; 8(10):1273-99. PubMed ID: 23130928
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Dendritic cell-based immunotherapy in multiple myeloma.
    Yi Q
    Leuk Lymphoma; 2003 Dec; 44(12):2031-8. PubMed ID: 14959845
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Optimal therapeutic strategy using antigen-containing liposomes selectively delivered to antigen-presenting cells.
    Iyoda T; Yamasaki S; Kawamura M; Ueda M; Son K; Ito Y; Shimizu K; Fujii SI
    Cancer Sci; 2019 Mar; 110(3):875-887. PubMed ID: 30629329
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Restoring immunosurveillance by dendritic cell vaccines and manipulation of the tumor microenvironment.
    Vasaturo A; Verdoes M; de Vries J; Torensma R; Figdor CG
    Immunobiology; 2015 Feb; 220(2):243-8. PubMed ID: 25466585
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Dendritic cell vaccines.
    Mosca PJ; Lyerly HK; Clay TM; Morse MA; Lyerly HK
    Front Biosci; 2007 May; 12():4050-60. PubMed ID: 17485358
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Dendritic cell-based immunotherapy: a potential player in oral cancer therapeutics.
    Dwivedi R; Pandey R; Chandra S; Mehrotra D
    Immunotherapy; 2023 Apr; 15(6):457-469. PubMed ID: 37013843
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Biomaterial-based platforms for in situ dendritic cell programming and their use in antitumor immunotherapy.
    Calmeiro J; Carrascal M; Gomes C; Falcão A; Cruz MT; Neves BM
    J Immunother Cancer; 2019 Sep; 7(1):238. PubMed ID: 31484548
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Induction of immune tolerance by dendritic cells: implications for preventative and therapeutic immunotherapy of autoimmune disease.
    Thompson AG; Thomas R
    Immunol Cell Biol; 2002 Dec; 80(6):509-19. PubMed ID: 12406384
    [TBL] [Abstract][Full Text] [Related]  

  • 72. IL-33 and IL-33-derived DC-based tumor immunotherapy.
    Kang MH; Bae YS
    Exp Mol Med; 2024 Jun; 56(6):1340-1347. PubMed ID: 38825642
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Trial watch: Dendritic cell (DC)-based immunotherapy for cancer.
    Laureano RS; Sprooten J; Vanmeerbeerk I; Borras DM; Govaerts J; Naulaerts S; Berneman ZN; Beuselinck B; Bol KF; Borst J; Coosemans A; Datsi A; Fučíková J; Kinget L; Neyns B; Schreibelt G; Smits E; Sorg RV; Spisek R; Thielemans K; Tuyaerts S; De Vleeschouwer S; de Vries IJM; Xiao Y; Garg AD
    Oncoimmunology; 2022; 11(1):2096363. PubMed ID: 35800158
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Dendritic cell vaccine and cancer treatment: new patents.
    Aleixo AA; Michelin MA; Murta EF
    Recent Pat Endocr Metab Immune Drug Discov; 2014 Jan; 8(1):26-9. PubMed ID: 24397783
    [TBL] [Abstract][Full Text] [Related]  

  • 75. [Dendritic cells and gliomas: a hope in immunotherapy?].
    Jouanneau E; Poujol D; Caux C; Belin MF; Blay JY; Puisieux I;
    Neurochirurgie; 2006 Dec; 52(6):555-70. PubMed ID: 17203907
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Let's fight cancer: let-7 is a tool to enhance antitumor immune responses.
    Pobezinsky LA; Wells AC
    Future Oncol; 2018 May; 14(12):1141-1145. PubMed ID: 29683340
    [No Abstract]   [Full Text] [Related]  

  • 77. Cellular immunotherapy: a clinical state-of-the-art of a new paradigm for cancer treatment.
    Rodríguez Pérez Á; Campillo-Davo D; Van Tendeloo VFI; Benítez-Ribas D
    Clin Transl Oncol; 2020 Nov; 22(11):1923-1937. PubMed ID: 32266674
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Dendritic cells the tumor microenvironment and the challenges for an effective antitumor vaccination.
    Benencia F; Sprague L; McGinty J; Pate M; Muccioli M
    J Biomed Biotechnol; 2012; 2012():425476. PubMed ID: 22505809
    [TBL] [Abstract][Full Text] [Related]  

  • 79. RNA transfer and its use in dendritic cell-based immunotherapy.
    Gust TC; Zenke M
    Expert Opin Biol Ther; 2005 Feb; 5(2):173-81. PubMed ID: 15757379
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Dendritic Cells in Colorectal Cancer and a Potential for their Use in Therapeutic Approaches.
    Chistiakov DA; Orekhov AN; Bobryshev YV
    Curr Pharm Des; 2016; 22(16):2431-8. PubMed ID: 26845127
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.